Moderna, Inc.
Moderna, Inc. (MRNA) Financial Performance & Income Statement Overview
Analyze Moderna, Inc. (MRNA) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
Moderna, Inc. (MRNA) Income Statement & Financial Overview
Review Moderna, Inc. MRNA income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $107.00M | $956.00M | $1.85B | $221.00M |
| Cost of Revenue | $90.00M | $739.00M | $514.00M | $115.00M |
| Gross Profit | $17.00M | $217.00M | $1.34B | $106.00M |
| Gross Profit Ratio | $0.16 | $0.23 | $0.72 | $0.48 |
| R&D Expenses | $856.00M | $1.12B | $1.14B | $1.22B |
| SG&A Expenses | $212.00M | $351.00M | $281.00M | $268.00M |
| Operating Expenses | $1.07B | $1.46B | $1.41B | $1.47B |
| Total Costs & Expenses | $1.16B | $2.20B | $1.93B | $1.58B |
| Interest Income | $90.00M | $91.00M | $103.00M | $111.00M |
| Interest Expense | $1.00M | $6.00M | $6.00M | $6.00M |
| Depreciation & Amortization | $39.00M | $60.00M | $52.00M | $41.00M |
| EBITDA | -$924.00M | -$1.12B | $79.00M | -$1.23B |
| EBITDA Ratio | -$8.64 | -$1.17 | $0.04 | -$5.57 |
| Operating Income | -$1.05B | -$1.25B | -$70.00M | -$1.36B |
| Operating Income Ratio | -$9.81 | -$1.30 | -$0.04 | -$6.17 |
| Other Income/Expenses (Net) | $86.00M | $62.00M | $91.00M | $84.00M |
| Income Before Tax | -$964.00M | -$1.18B | $21.00M | -$1.28B |
| Income Before Tax Ratio | -$9.009 | -$1.24 | $0.01 | -$5.79 |
| Income Tax Expense | $7.00M | -$64.00M | $8.00M | $0.00 |
| Net Income | -$971.00M | -$1.12B | $13.00M | -$1.28B |
| Net Income Ratio | -$9.07 | -$1.17 | $0.007 | -$5.79 |
| EPS | -$2.52 | -$2.91 | $0.03 | -$3.33 |
| Diluted EPS | -$2.52 | -$2.91 | $0.03 | -$3.33 |
| Weighted Avg Shares Outstanding | $386.00M | $385.00M | $385.00M | $384.00M |
| Weighted Avg Shares Outstanding (Diluted) | $386.00M | $385.00M | $399.00M | $384.00M |
Over the past four quarters, Moderna, Inc. demonstrated steady revenue growth, increasing from $221.00M in Q2 2024 to $107.00M in Q1 2025. Operating income reached -$1.05B in Q1 2025, maintaining a consistent -981% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$924.00M, reflecting operational efficiency. Net income rose to -$971.00M, with EPS at -$2.52. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan